| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK |
2019-10-15 |
| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-15 |
| CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP |
2019-10-15 |
| Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics |
2019-10-10 |
| FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck |
2019-10-10 |
| Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health |
2019-10-09 |
| Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data |
2019-10-09 |
| Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation |
2019-10-08 |
| GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies |
2019-10-08 |
| Vivoryon–MC Services: public relations, 201910 service existent by MC Services |
2019-10-08 |
| Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG |
2019-10-08 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-08 |
| 4SC–SEVERAL: investment, 201910–201911 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights |
2019-10-07 |
| 4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS |
2019-10-07 |
| Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity |
2019-10-07 |
| Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w |
2019-10-07 |
| Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery |
2019-10-07 |
| Rentschler–Sumitomo: biologics contract manufacturing, 201910– collab expansion SPI supports marketing + delivery of Rentschler CDMO services in Japan |
2019-10-04 |
| Aeovian Pharmaceuticals–Apollo Health Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo HV |
2019-10-03 |
| Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec |
2019-10-03 |
| Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners |
2019-10-03 |
| Freiberg Instruments–Bruker: investment, 201910 acquisition €na of Magnettech EPR business by Bruker |
2019-10-02 |
| Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) |
2019-10-01 |
| Eisai–Numab: antibody cancer drug, 201910– collab + license option ww excl developing multi-specific Abs using MATCH platform |
2019-10-01 |
| Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug RnD + commercialisation |
2019-10-01 |
| Creoptix–SEVERAL: investment, 201909 financing round Series 1st closing CHF8m incl investors Swisscanto Invest + Waters |
2019-09-30 |
| Creoptix–Waters: investment, 201909 financing round Series 1st closing totalling CHF8m incl existing + co-investor Waters Corp |
2019-09-30 |
| Creoptix–Zürcher Kantonalbank: investment, 201909 financing round Series 1st closing totalling CHF8m incl new + lead investor Swisscanto Invest |
2019-09-30 |
| STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings |
2019-09-30 |
| Roper Technologies–AMETEK: investment, 201909– acquisition $925m in cash of Gatan Inc from Roper Technologies by AMETEK |
2019-09-27 |
| T3 Pharmaceuticals–Boehringer: investment, 201909 2nd financing round totalling CHF12m incl new investor BIVF |
2019-09-26 |
| T3 Pharmaceuticals–Reference Capital: investment, 201909 2nd financing round totalling CHF12m incl new investor Reference Capital SA |
2019-09-26 |
| T3 Pharmaceuticals–SEVERAL: investment, 201909 2nd financing round CHF12m incl new investors BIVF + Reference Capital SA |
2019-09-26 |
| Tacalyx–Boehringer: investment, 201909 seed financing round totalling €7m incl co-lead investor BIVF |
2019-09-25 |
| Tacalyx–Creathor Ventures: investment, 201909 seed financing round totalling €7m incl co-investor Creathor Ventures |
2019-09-25 |
| Tacalyx–Eurazeo: investment, 201909 seed financing round totalling €7m incl co-investor Idinvest Partners |
2019-09-25 |
| Tacalyx–Germany (govt): investment, 201909 seed financing round totalling €7m incl co-investor Coparion |
2019-09-25 |
| Tacalyx–High-Tech Gründerfonds: investment, 201909 seed financing round totalling €7m incl co-investor HTGF |
2019-09-25 |
| Tacalyx–Huntsworth: public relations, 201909 service existent by Citigate Dewe Rogerson |
2019-09-25 |
| Tacalyx–Kurma: investment, 201909 seed financing round totalling €7m incl co-lead investor Kurma Partners |
2019-09-25 |
| Tacalyx–Max Planck: antibody discovery technology, 201909c license to plaQorm technology of MPI of Colloids + Interfaces from Max Planck Innovation |
2019-09-25 |
| Tacalyx–SEVERAL: investment, 201909 seed financing round €7m co-led by BIVF + Kurma Partners |
2019-09-25 |
| Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) |
2019-09-24 |
| Takeda–Evotec: drug discovery services, 201909– collab strategic multi-year across multiple indications |
2019-09-24 |
| AC Immune–LaVoieHealthScience: public relations, 201909– supply service existent US media relations by LHS |
2019-09-20 |
| AC Immune–LifeSci: public relations, 201909 supply service existent European investor + media relations by LifeSci Advisors |
2019-09-20 |
| Boehringer–Inflammasome: drug delivery technology, 201909– co-developm + license up to 3 retinal disease therapies using IVT drug delivery |
2019-09-20 |
| Bruker–Murdoch Univ: analytical technologies, 201909– collab strategic alliance with ANPC incl MS + NMR for phenomics research |
2019-09-20 |
| Murdoch Univ–Bruker: NMR spectrometer, 201909 supply NMR FoodScreener |
2019-09-20 |
| Oncimmune–IPF Partners: credit, 201909– 202309 credit facility €8.5m four year incl warrant for 2m new ordinary shares IPF Management SA |
2019-09-20 |
| Novigenix–BioLizard: bioinformatics, 201909– collab developm of AI-based bioinformatics algorithm to support developm of tests for LITOseek platform |
2019-09-19 |
| Themis Bioscience–Farallon Capital: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Farallon Capital |
2019-09-18 |
| Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures |
2019-09-18 |
| Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures |
2019-09-18 |
| Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB |
2019-09-18 |
| Bayer–Informed Data Systems: digital health, 201909– collab + licensing agreem $10m developm + commercialisaing of One Drop technology platform |
2019-09-17 |
| Informed Data Systems–Bayer: investment, 201909 Series B financing incl $20m from Bayer |
2019-09-17 |
| Life Healthcare Group–AC Immune: PET tracer, 201909 collab existent developm Tau PET tracer PI-2620 with Life Molecular Imaging |
2019-09-17 |
| Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners |
2019-09-17 |
| Belyntic–Berlin (govt): investment, 201909 seed financing round totalling €1.3m incl lead investor IBB |
2019-09-16 |
| Belyntic–High-Tech Gründerfonds: investment, 201909 seed financing round totalling €1.3m incl co-investor HTGF |
2019-09-16 |
| Belyntic–PERSON: investment, 201909 seed financing round totalling €1.3m incl co-investor business angel Till Knorr |
2019-09-16 |
| Belyntic–SEVERAL: investment, 201909 seed financing round €1.3m led by IBB + incl HTGF + business angel Till Knorr |
2019-09-16 |
| GenomSys–Club degli Investitori: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Club degli Investitori |
2019-09-16 |
| GenomSys–Dolby Family Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Dolby Family Ventures |
2019-09-16 |
| GenomSys–Elysia Capital: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Elysia Capital |
2019-09-16 |
| GenomSys–Preon Capital: investment, 201909 financing round Series A totalling CHF9.3m incl lead investor Preon Capital |
2019-09-16 |
| GenomSys–Pygar: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Pygar family office |
2019-09-16 |
| GenomSys–SEVERAL: investment, 201909 financing round Series A CHF9.3m led by Preon Capital |
2019-09-16 |
| GenomSys–Susman Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Susman Ventures |
2019-09-16 |
| OTHER–Curetis: molecular diagnostics, 201909– collab RnD + option for NGS-based antibiotic resistance testing of Ares Genetics with global IVD firm |
2019-09-16 |
| Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures |
2019-09-12 |
| Khanu Management–Austria (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl aws |
2019-09-12 |
| Khanu Management–EU (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl European Investment Fund |
2019-09-12 |
| Khanu Management–Max Planck: investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl Max Planck Foundation |
2019-09-12 |
| Khanu Management–SEVERAL: investment, 201909 1st closing €60m of KHAN Technology Transfer Fund I |
2019-09-12 |
| Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule RnD to Orion Pharma |
2019-09-11 |
| Bayer–Minapharm: GlymaxX technology, 201909– license for use in cell line developm for cancer antibody candidate of Bayer |
2019-09-10 |
| Grünenthal–Mesoblast: cell therapy, 201909– strategic collab $15m upfront developm + commercialisation of MPC-06-ID in Europe + Lation America |
2019-09-10 |
| BioNTech–SEVERAL: investment, 201909–201910 US IPO $150m+$22.5m with 10m+1.5mADSs at $15/ADS at Nasdaq Global Select Market |
2019-09-09 |
| ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 |
2019-09-06 |
| iStar Medical–SEVERAL: investment, 201905 financing round Series C €40m led by LSP + Gimv |
2019-09-05 |
| PathoQuest–SEVERAL: investment, 201909 financing round €7.57m incl venture loan from Norgine Ventures |
2019-09-05 |
| Roche–Abionic: in vitro diagnostics, 201909– collab developm + supply abioSCOPE IVD PoC asthma test panel for asthma management in US for Genentech |
2019-09-05 |
| BioNTech–Gates Foundation: investment, 201909 equity investment $55m in connection with anti-infectives collaboration |
2019-09-04 |
| Boehringer–Lupin: MEK inhibitor, 201909– license $20m upfront + $700m milestones + royalties to LNP3794 for combi with KRAS inhibitors for cancer |
2019-09-04 |
| Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity |
2019-09-04 |
| Gates Foundation–BioNTech: anti-infectives, 201909– collab developm of HIV + TB immunotherapies with up to $100m funding incl equity investment $55m |
2019-09-04 |
| FU Berlin–Agilent: mass spectrometer, 201909 supply existent LC/MS/MS + GC/MS systems at FU Berlin used in doping control study with Agilent support |
2019-09-03 |
| Grünenthal–Univ Queensland: pain drugs, 201909– collab develop therapies derived from group of alpha-conotoxins for chronic neuropathic pain |
2019-09-03 |
| Univ College London–Bruker: atomic force microscope, 201908 supply existent London Centre for Nanotechnology long-term user of NanoWizard systems |
2019-09-02 |
| Biocrates–MIG Founds: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure |
2019-09-01 |
| Biocrates–SEVERAL: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure |
2019-09-01 |
| Biocrates–Xolaris Service KVG: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure |
2019-09-01 |
| Celgene–Immatics: cell therapy, 201908– strategic collab + excl option $75m upfront + $1.5b milestones + royalties for three TCR-T targets |
2019-08-28 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 24 25 26 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
